ZA888981B - D-cycloserine and its prodrugs as cognitive enhancers - Google Patents

D-cycloserine and its prodrugs as cognitive enhancers

Info

Publication number
ZA888981B
ZA888981B ZA888981A ZA888981A ZA888981B ZA 888981 B ZA888981 B ZA 888981B ZA 888981 A ZA888981 A ZA 888981A ZA 888981 A ZA888981 A ZA 888981A ZA 888981 B ZA888981 B ZA 888981B
Authority
ZA
South Africa
Prior art keywords
cycloserine
prodrugs
cognitive enhancers
cognitive
enhancers
Prior art date
Application number
ZA888981A
Other languages
English (en)
Inventor
Alex A Cordi
A Cordi Alex
Gail E Handelmann
E Handelmann Gail
Joseph B Monahan
B Monahan Joseph
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of ZA888981B publication Critical patent/ZA888981B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA888981A 1987-12-01 1988-11-30 D-cycloserine and its prodrugs as cognitive enhancers ZA888981B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers

Publications (1)

Publication Number Publication Date
ZA888981B true ZA888981B (en) 1990-01-31

Family

ID=22428413

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA888981A ZA888981B (en) 1987-12-01 1988-11-30 D-cycloserine and its prodrugs as cognitive enhancers

Country Status (20)

Country Link
US (1) US4904681A (enExample)
EP (2) EP0319824B1 (enExample)
JP (2) JPH0621065B2 (enExample)
KR (1) KR0134198B1 (enExample)
AT (1) ATE68698T1 (enExample)
AU (4) AU622630B2 (enExample)
CA (1) CA1328617C (enExample)
DE (1) DE3865817D1 (enExample)
DK (1) DK173589B1 (enExample)
ES (1) ES2040314T3 (enExample)
FI (1) FI885559A0 (enExample)
GR (1) GR3003571T3 (enExample)
IE (1) IE61825B1 (enExample)
IL (1) IL88531A (enExample)
NO (1) NO885337D0 (enExample)
NZ (1) NZ227131A (enExample)
PH (1) PH26467A (enExample)
PT (1) PT89109B (enExample)
WO (1) WO1989005144A1 (enExample)
ZA (1) ZA888981B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
AU4019395A (en) 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
AU4128896A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
CA2216648A1 (en) * 1995-02-15 1996-08-22 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
IL124536A (en) * 1995-12-07 2001-03-19 Daniel C Javitt Pharmaceutical compositions containing a glycine uptake antagonist
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
ES2262322T3 (es) 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
US7750030B2 (en) * 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
CA2442798A1 (en) * 2001-04-02 2002-10-10 Panorama Research, Inc. Antioxidant nitroxides and nitrones as therapeutic agents
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
WO2005000216A2 (en) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
CA2534909A1 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
KR101769999B1 (ko) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2789331C (en) 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
PE20151436A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung

Also Published As

Publication number Publication date
EP0421997A1 (en) 1991-04-17
FI885559A0 (fi) 1988-11-30
EP0319824B1 (en) 1991-10-23
GR3003571T3 (enExample) 1993-03-16
DK173589B1 (da) 2001-04-02
AU2631988A (en) 1989-06-01
PT89109A (pt) 1989-12-29
JPH01193220A (ja) 1989-08-03
IE883567L (en) 1989-06-01
ATE68698T1 (de) 1991-11-15
PT89109B (pt) 1993-07-30
JPH05201859A (ja) 1993-08-10
DK669088D0 (da) 1988-11-30
CA1328617C (en) 1994-04-19
US4904681A (en) 1990-02-27
DK669088A (da) 1989-06-02
KR0134198B1 (ko) 1998-04-21
NZ227131A (en) 1991-09-25
AU2813089A (en) 1989-07-05
AU622630B2 (en) 1992-04-16
PH26467A (en) 1992-07-27
DE3865817D1 (enExample) 1991-11-28
JPH0621065B2 (ja) 1994-03-23
EP0319824A1 (en) 1989-06-14
WO1989005144A1 (en) 1989-06-15
KR890009392A (ko) 1989-08-01
IL88531A0 (en) 1989-06-30
ES2040314T3 (es) 1995-04-01
IL88531A (en) 1993-02-21
IE61825B1 (en) 1994-11-30
AU1083992A (en) 1992-05-07
NO885337D0 (no) 1988-11-30
AU7746794A (en) 1995-01-05

Similar Documents

Publication Publication Date Title
ZA888981B (en) D-cycloserine and its prodrugs as cognitive enhancers
DE3779053D1 (enExample)
GB8704032D0 (en) Light emitter bias stabilization
EP0563345A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
CA2030345A1 (en) Use of 15-keto-prostaglandin compound for improvement of encephalic function
NO174807C (enExample)
GR3004959T3 (enExample)
FI945626A0 (fi) Menetelmä 2,2-difluoriketeenisilyyliasetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihappoestereiden valmistamiseksi
EP0171628A3 (en) Novel non-dusting antibiotic anticoccidial premix compositions and a process for their manufacture
PH25095A (en) Beta-alkylmelatonins
EP0405905A3 (en) Use of isoxazolin-3-one derivatives as antidepressants
EP0612750A3 (en) Cephalosporinderivatives.
DE3476065D1 (en) L-arginine isoxicamate
FR2623772B1 (fr) Perfectionnements apportes aux enrouleurs de voiles, notamment aux enrouleurs de grand-voiles
FR2621212B1 (fr) Perfectionnement aux roues de plombage des semoirs
FR2611460B1 (fr) Perfectionneme nts aux etageres
FR2627937B2 (fr) Perfectionnement aux roues de plombage des semoirs
AU554777B2 (en) Benzoquinolizines